Ruti Aga: Six Years, One Forged Prescription, and the Winning Time Nobody Printed

Let me start where the room went quiet. The statement the Athletics Integrity Unit (AIU) released on Thursday carries six years, the name of a drug, and a date — 10 September. What it does not carry is the time in which Ruti Aga won a half marathon in China in March.

A sport that keeps its books in seconds produced a disciplinary verdict without a single second in it. The statement says the sample taken after that race was positive. It does not say which race, which year, what the winning mark was, or how strong the field was. In a discipline where even split times get published, that absence is a document in itself.

The heaviest exhibit in this case is not a positive sample. It is a piece of paper — a prescription that fell down three separate times in three separate verifications. According to the AIU, the clinic the slip came from did not exist. The person who signed it was a family member with no medical registration. And when asked where the paper came from, the answer was that it was an "old prescription pad from a former workplace" — a pad the clinic flatly disowned.

One slip, three checks, three failures. That is the real subject here, and it is the thing that takes this out of the doping-report folder and into the story of medical governance.

If you have never watched a marathon, one sentence: in a 42-kilometre race, an athlete's income comes less from running than from saying yes to running — from flying to that city, standing in that field, wearing that bib. Ruti Aga sat on the upper shelf of that economy, and one evening on that shelf she won in China.

Ruti Aga of Ethiopia, 32. The public race record shows 2:18:34 for second place at the 2026 Berlin Marathon and 2:20:40 for the win at Tokyo in 2026, plus three runner-up finishes at World Marathon Majors. Those numbers are not in the AIU statement; they come from race history, and in this case they have exactly one job — to establish that this was not a marginal runner. This was a 2:18 woman.

Set a second number beside them: zero global championship medals. In Ethiopia, 2:18:34 is not an automatic national-team ticket. There is a queue of women running under 2:16. The removal of one athlete does not move Ethiopia's medal capacity by any margin that shows up in a table.

The race she was caught in was not the biggest race of her career. Label road races in China sit on the strip where Ethiopian and Kenyan marathoners go between Majors to collect appearance fees. Few races, high fees, name recognition. In road racing the in-competition testing window opens at 23:59 the day before the race — which means the injection that was entirely legal four days out gets caught on race day.

The drug is methylprednisolone, and this is where the first correction belongs. Early reporting called it a "prohibited steroid." That is wrong. Methylprednisolone is not an anabolic steroid; it is a glucocorticoid, class S9 on the WADA Prohibited List, not S1. And the crucial condition on S9 is that it is prohibited in-competition only, and only by injection, oral or rectal route.

That single fact moves the entire case. The question was never "steroid use." The question was route of administration and proximity to competition. Intra-articular methylprednisolone for knee synovitis is routine sports medicine in distance runners. Out of competition it is entirely legal. The problem was not the drug. The problem was timing and paperwork.

An old question surfaces here. In 2026, when the Tokyo Olympics were postponed and the national camp at Patiala shut, I made thirty-four calls to women athletes. From those calls I learned that the first question is not "what is your target" but "who pays your rent." Apply that question here and the statement gives you nothing. The AIU tells us the prescription was forged; it does not tell us whether the athlete had a credentialed team doctor at all.

The sanction arithmetic is plain, and the whole story sits inside it. Two years for the presence violation, four years for tampering. Six in total. Two years is the standard sanction when the substance is a specified substance and intent is not proven. Four years is the standard Code sanction for tampering.

The arithmetic makes one thing clear: the panel rejected the no-significant-fault mitigation. Had real medical records existed, had a route-and-timing explanation held, the presence charge could have been argued down sharply — and the tampering charge would never have been drafted. Four of those six years are the penalty for fabricating a defence.

Backdating the ban to 10 September is not leniency. Provisional suspension time is credited against the period; it is time she was already out. Reading it as a reduction is the mistake every disciplinary write-up repeats.

What was actually available is the question worth asking. Two options were open. First, a Therapeutic Use Exemption, which a documented knee injection could have supported. Second, adherence to WADA's route-specific washout, spacing the injection so no residue remained on race day. Neither happened. When the test came back, a prescription was manufactured.

This case is unusual because the athlete destroyed her own strongest defence. An in-competition glucocorticoid finding with a legitimate clinical basis is not normally a long-ban case. The forged slip made it one.

Now the part with no word in any statement: the knee. Chronic knee pathology is a known failure mode in marathoners — 180 to 200 kilometres a week, and the joint that absorbs it. The AIU statement cites a knee injury as the reason for treatment. That is mechanically plausible. And the plausibility is precisely what makes the forgery decisive: a genuinely documented treatment gets defended with real records, not invented ones.

From here the picture widens. The road-running world of Ethiopia and Kenya carries an entire professional layer — agents, camps, training groups, and a medical network that is not always credentialed. Dozens of athletes live in the same altitude camp, see the same physio, share the same injection vials. Doping investigation arrives in that structure at a place clinical governance never reached.

So when the AIU says the signing "doctor" was an unregistered family member, it is not describing one person's dishonesty. It is describing a career with nobody whose job was to know when the injection goes in, how much, and what date the race falls on. A 32-year-old marathoner had a 2:18 body and not one credentialed team physician.

The economics are just as visible. Appearance fees dominate a road runner's income, and those fees depend on looking fit enough to run. A sore knee three weeks out creates a financial incentive to mask pain. A glucocorticoid is the cheapest, most available answer to that incentive. The forged prescription is downstream of the pressure, not the source of it.

And the circuit where this happened has quietly become the most scrutinised tier in the sport. Large appearance-fee budgets, deep East African elite fields and AIU testing now meet in the same Chinese label races. What was described as a low-risk, high-income tier is now the highest-yield testing ground. The fee economy and the testing economy are colliding in the same race.

The career maths matters, because it is where this case separates from others. Three World Marathon Majors runner-up finishes is not a small record. Berlin 2026's 2:18:34 and Tokyo 2026's 2:20:40 are the permanent record of a genuinely elite athlete. The violation is anchored to a March race in a later year, and absent a finding of earlier use, results before that date are not automatically annulled. The 2026 Tokyo title is not a title a press release erases.

The result most likely to fall is the March race and its prize money; standard AIU practice voids the competition at which the sample was collected. The statement does not state the disqualification scope. That is the same silence I logged at the start.

When I watched the 2026 Tokyo Marathon I was twenty, a broadcasting student at a desk in Mumbai, and it took the whole race for 2:20 to stop looking like a number and start looking like a speed. What stayed with me was not the clock. It was that the finish-line camera goes to the faces that win, and not to the hands holding bottles behind them. Five years on, that athlete became two lines in a release.

That is where a habit of mine had to change. I kept the tape running after the questions ran out. In the AIU statement I went looking for what was not there: a national federation response. The Ethiopian federation's position on this case is not quoted. An athlete who won a Major is gone for six years and her federation is silent. That silence is as reportable as the ban.

Here is where I part company with the easy reading. Six years landed on a drug with no proven endurance benefit. A glucocorticoid reduces pain and swelling; it does not raise haemoglobin, build muscle or carry oxygen. Several anabolic-steroid cases have drawn shorter periods. This sanction was imposed on a piece of paper, not on a drug — and that distinction is the whole case.

Which produces an easy counter-narrative: enforcement against African road runners is disproportionate. That narrative is part of the truth and not the whole of it. The tier where the AIU tests hardest is the tier where the most Ethiopian and Kenyan runners race — that is bias and geography at once. But in this case the tampering was not imposed on the athlete. The slip was commissioned.

What breaks the disproportionality frame is that the real indictment is not against a person but against an absence. A 32-year-old with a chronic knee, an income tied to appearance fees, and a national queue running under 2:16 — had one professional been tracking dates and doses, this case would not exist. The penalty belongs to the paper. The question belongs to the system that made the paper necessary.

This case is not an isolated one. The East African road-racing files of recent years show a pattern: the first violation involves a substance, and the second — the bigger one — involves the explanation. Paper gets produced, signatures get added, a clinic gets named, and the investigation arrives where the clinic does not exist. Anti-doping's next fight will be fought over document verification, not over samples.

Nobody is prepared for that shift. The athlete has no team doctor, the agent has no medical protocol, the federation has no statement. As long as the investigative weight sits on samples alone, the athletes caught will keep being the ones who forge the worst paperwork — and they will keep receiving the longest bans.

If you came for a scoreboard, there isn't one. The medal table did not move, Ethiopia's depth did not thin, the world rankings did not shift. What changed is one life — a ban running from 32 to roughly 38, the decade in which marathoners run their second and third best races. A return at 38, against a generation running under 2:16.

And the time she ran in the race that caught her is still not printed anywhere. It sounds small. It is the cleanest symbol in the file: we have read the end of a career and we still do not know how fast her last win was.

Two questions decide what comes next. Whether the AIU makes document verification a formal step rather than a case-by-case accident. And the harder one — whether any federation or agency has started treating a team doctor as a condition of racing rather than a luxury. The day that line appears in a budget, slips like this stop being manufactured. Until then, behind every six-year ban sits a question the statement never asked: who was treating the knee?